These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 9656753)
21. Trends in incidence and survival of mesenchymal neoplasm of the digestive tract within a defined population of northern Norway. Steigen SE; Eide TJ APMIS; 2006 Mar; 114(3):192-200. PubMed ID: 16643186 [TBL] [Abstract][Full Text] [Related]
22. Gastrointestinal stromal tumors: usefulness of immunohistochemistry, flow cytometry and fluorescence in situ hybridization. Fontana MG; Rossi E; Bassotti G; Aquilano MC; Cadei M; Grigolato P; Villanacci V J Gastroenterol Hepatol; 2007 Nov; 22(11):1754-9. PubMed ID: 17914946 [TBL] [Abstract][Full Text] [Related]
23. Serosal penetration is an important prognostic factor for gastrointestinal stromal tumors. Vallböhmer D; Marcus HE; Baldus SE; Brabender J; Drebber U; Metzger R; Hölscher AH; Schneider PM Oncol Rep; 2008 Oct; 20(4):779-83. PubMed ID: 18813818 [TBL] [Abstract][Full Text] [Related]
24. Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients. Bodner K; Bodner-Adler B; Obermair A; Windbichler G; Petru E; Mayerhofer S; Czerwenka K; Leodolter S; Kainz C; Mayerhofer K Gynecol Oncol; 2001 May; 81(2):160-5. PubMed ID: 11330943 [TBL] [Abstract][Full Text] [Related]
25. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Rutkowski P; Nowecki ZI; Michej W; Debiec-Rychter M; Woźniak A; Limon J; Siedlecki J; Grzesiakowska U; Kakol M; Osuch C; Polkowski M; Głuszek S; Zurawski Z; Ruka W Ann Surg Oncol; 2007 Jul; 14(7):2018-27. PubMed ID: 17473953 [TBL] [Abstract][Full Text] [Related]
26. Audit of a series of 40 gastrointestinal stromal tumour cases. Hinz S; Pauser U; Egberts JH; Schafmayer C; Tepel J; Fändrich F Eur J Surg Oncol; 2006 Dec; 32(10):1125-9. PubMed ID: 16859873 [TBL] [Abstract][Full Text] [Related]
27. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors. Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300 [TBL] [Abstract][Full Text] [Related]
28. Time dependence of prognostic factors for patients with soft tissue sarcoma: a Scandinavian Sarcoma Group Study of 338 malignant fibrous histiocytomas. Engellau J; Anderson H; Rydholm A; Bauer HC; Hall KS; Gustafson P; Akerman M; Meis-Kindblom J; Alvegård TA; Nilbert M; Cancer; 2004 May; 100(10):2233-9. PubMed ID: 15139069 [TBL] [Abstract][Full Text] [Related]
29. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Strosberg J; Nasir A; Coppola D; Wick M; Kvols L Hum Pathol; 2009 Sep; 40(9):1262-8. PubMed ID: 19368957 [TBL] [Abstract][Full Text] [Related]
31. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. Colman H; Giannini C; Huang L; Gonzalez J; Hess K; Bruner J; Fuller G; Langford L; Pelloski C; Aaron J; Burger P; Aldape K Am J Surg Pathol; 2006 May; 30(5):657-64. PubMed ID: 16699322 [TBL] [Abstract][Full Text] [Related]
32. Significance of p53 expression in gastrointestinal stromal tumors. Yalcinkaya U; Yerci O; Koc EU Hepatogastroenterology; 2007; 54(73):140-3. PubMed ID: 17419248 [TBL] [Abstract][Full Text] [Related]
33. The relationship between MIB-1 proliferative activity and mitotic index in gastrointestinal stromal tumors. Filiz G; Yalçinkaya O; Gürel S; Yerci O; Memik F Hepatogastroenterology; 2007 Mar; 54(74):438-41. PubMed ID: 17523292 [TBL] [Abstract][Full Text] [Related]
34. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium. Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909 [TBL] [Abstract][Full Text] [Related]
35. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899 [TBL] [Abstract][Full Text] [Related]
36. Endoluminal resection for sessile neoplasia in the GI tract is associated with a low recurrence rate and a high 5-year survival rate. Wang AY; Ahmad NA; Zaidman JS; Brensinger CM; Lewis JD; Long WB; Kochman ML; Ginsberg GG Gastrointest Endosc; 2008 Jul; 68(1):160-9. PubMed ID: 18577483 [TBL] [Abstract][Full Text] [Related]
37. Surgery and prognostic factors for gastric stromal tumor. Kwon SJ; World J Surg; 2001 Mar; 25(3):290-5. PubMed ID: 11343178 [TBL] [Abstract][Full Text] [Related]
38. Comparative analysis of four histopathological classification systems to discriminate benign and malignant behaviour in gastrointestinal stromal tumors. Vallböhmer D; Marcus HE; Baldus SE; Brabender J; Lurje G; Drebber U; Metzger R; Hölscher AH; Schneider PM Anticancer Res; 2008; 28(1B):367-72. PubMed ID: 18383871 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of gastrointestinal stromal tumors for recurrence rates and patterns of long-term follow-up. Samiian L; Weaver M; Velanovich V Am Surg; 2004 Mar; 70(3):187-91; discussion 191-2. PubMed ID: 15055839 [TBL] [Abstract][Full Text] [Related]
40. Gastrointestinal stromal tumors the assessment of malignant potential. Nada R; Vaiphei K; Singh R; Wig JD; Gupta NM; Banerjee AK Indian J Pathol Microbiol; 2001 Oct; 44(4):393-7. PubMed ID: 12035347 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]